Natco Pharma Limited has formally intimated the Bombay Stock Exchange Limited (BSE) and the National Stock Exchange of India Limited (NSE) about receiving in-principle approval for a Rights Issue of fully paid-up equity shares.
The company received the in-principle approval from both stock exchanges on September 21, 2026. The approval letters from the stock exchanges have been made available on the company's official website at https://files.natcopharma.co.in/investor-relations/rights-issue-2026/ for investor access.
The disclosure was signed by Ch. Venkat Ramesh (also digitally signed as VENKAT RAMESH CHEKURI), who serves as the Company Secretary & Compliance Officer of Natco Pharma Limited. The digital signature was timestamped on September 21, 2026, at 20:37:19 IST.
This communication serves as a regulatory compliance disclosure under applicable listing regulations, formally notifying the exchanges about the approval received for the proposed corporate action.